Cost-effectiveness of Medical Expulsive Therapy with ?-blockers for Large Distal Ureteral Stones in China.

08:00 EDT 14th March 2020 | BioPortfolio

Summary of "Cost-effectiveness of Medical Expulsive Therapy with ?-blockers for Large Distal Ureteral Stones in China."

To assess the cost-effectiveness of medical expulsive therapy (MET) versus observation for large distal ureteral stones in China and provide preliminary evidence for the determination of the course of MET by mathematical estimation.


Journal Details

This article was published in the following journal.

Name: Urology journal
ISSN: 1735-546X


DeepDyve research library

PubMed Articles [28485 Associated PubMed Articles listed on BioPortfolio]

Efficacy of silodosin or mirabegron in medical expulsive therapy for ureteral stones: a prospective, randomized-controlled study.

To evaluate the efficacy of silodosin or mirabegron as a medical expulsive therapy for ureteric stones in adults.

Modelling the lifetime cost-effectiveness of catheter ablation for atrial fibrillation with heart failure.

Assessing the cost-effectiveness credentials of this intervention in patients with concomitant atrial fibrillation (AF) and heart failure (HF) compared with usual medical therapy.

Medical Expulsive Therapy (Alpha Blockers) for Urological Stone Disease.

Urinary tract stones are common and usually painful. Lifetime prevalence is approximately 10%. Direct healthcare costs are estimated to be over $10 billion dollars annually. First-line treatment is ty...

Cost-effectiveness of exercise therapy in patients with coronary heart disease, chronic heart failure and associated risk factors: A systematic review of economic evaluations of randomized clinical trials.

Prescribed exercise is effective in adults with coronary heart disease (CHD), chronic heart failure (CHF), intermittent claudication, body mass index (BMI) ≥25 kg/m, hypertension or type 2 diabete...

Re: Tamsulosin as a Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Clinical Trials [14100 Associated Clinical Trials listed on BioPortfolio]

Medical Expulsive Therapy of Single Distal Ureteral Stones

Current therapeutic options for ureteral stones include active intervention as well as conservative "watch and wait" approaches. Endoscopic treatment of ureteral stones has a high success ...

Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia

The primary objective of this trial is to compare the 9-month effect on lower urinary tract symptoms (LUTS) of Prostatic Artery Embolization (PAE) using Embosphere® versus Standard Combin...

External Physical Vibration Lithecbole(EPVL) Versus Traditional Row of Stone After Retrograde Intrarenal Surgery(RIRS)

The treatment of renal calculus by retrograde intrarenal surgery(RIRS) isn't able to eliminate stone completely, hastening fragments clearance just only rely on traditional expulsive metho...

Examining the Usage of Dopamine Blockers in OCD Patients

We examine the usage of Dopamine blockers in OCD patients. We want to examine their frequency of usage, compare the course of the disease between those who receive and those who do not rec...

Alfuzosin for Medical Expulsion Therapy of Ureteral Stones

The goal of this study is to conduct a prospective controlled trail of four currently approved Department of Defense (DOD) - formulary medications for use as medical expulsion therapy (MET...

Medical and Biotech [MESH] Definitions

A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.

Economic aspects of the fields of pharmacy and pharmacology as they apply to the development and study of medical economics in rational drug therapy and the impact of pharmaceuticals on the cost of medical care. Pharmaceutical economics also includes the economic considerations of the pharmaceutical care delivery system and in drug prescribing, particularly of cost-benefit values. (From J Res Pharm Econ 1989;1(1); PharmacoEcon 1992;1(1))

Organizations representing designated geographic areas which have contracts under the PRO program to review the medical necessity, appropriateness, quality, and cost-effectiveness of care received by Medicare beneficiaries. Peer Review Improvement Act, PL 97-248, 1982.

The personal cost of acute or chronic disease. The cost to the patient may be an economic, social, or psychological cost or personal loss to self, family, or immediate community. The cost of illness may be reflected in absenteeism, productivity, response to treatment, peace of mind, QUALITY OF LIFE, etc. It differs from HEALTH CARE COSTS, meaning the societal cost of providing services related to the delivery of health care, rather than personal impact on individuals.

The assignment, to each of several particular cost-centers, of an equitable proportion of the costs of activities that serve all of them. Cost-center usually refers to institutional departments or services.

Quick Search

DeepDyve research library

Searches Linking to this Article